Abstract 1339
Background
Esophageal squamous cell carcinoma (ESCC), a common gastrointestinal tumor, is listed as the sixth leading cause of cancer-related death worldwide, with high morbidity and mortality as its important characteristics. In recent years, despite advances in diagnosis and treatment of ESCC, the mortality rate of ESCC is still very high, with an average overall 5-year survival rate of about 10% ∼ 41%.As with many other solid tumors, development and progression of ESCC are also considered gene regulatory disorders caused by oncogene activation and inactivation accumulation and disorders of tumor suppressor genes (TSG). Therefore, screening and exploring the key gene proteins for the occurrence, development, treatment and clinical prognosis of ESCC is an important topic in the field of ESCC research at present.
Methods
Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical (IHC) staining were employed to determine IBSP expression at the mRNA and protein levels in clinical ESCC samples. Moreover, functional studies were adopted to study the tumor-promoter function of IBSP.
Results
IBSP up-regulation was found in 21 of 45 (46.7%) primary ESCC cells at mRNA level by transcription-polymerase chain reaction (RT-PCR). In addition, IHC staining further demonstrated that IBSP was up-regulated in ESCC cases and up-regulation of IBSP protein was significantly relevant to lymph node metastasis (P = 0.017), clinicopathologic stage (P = 0.001) and poor disease survival (P = 0.000) of ESCC patients. Moreover, functional studies illustrated that IBSP gene can promote the ability of proliferation and metastasis of ESCC cells. Furthermore, it was found that IBSP can regulate the EMT process by regulating MMP2 gene and N-cadherin, which promotes the metastasis of tumor cells.
Conclusions
the results of this study showed that IBSP up-regulation was often found in ESCC tumor specimens, indicating poor prognosis of ESCC patients. Moreover, it also demonstrated that IBSP could improve the ability of ESCC cell proliferation and tumor metastasis, which may be a valuable prognostic indicator in ESCC patients. Yet, the mechanism by which IBSP promotes tumorigenesis and development needs more researches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4321 - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study
Presenter: Annelies Boekhout
Session: Poster Display session 1
Resources:
Abstract
779 - Capecitabine vs Cisplatin along with concurrent radiotherapy in the treatment of inoperable lower esophageal cancers focusing on TWISTT score and QOL
Presenter: Goutham Anugu
Session: Poster Display session 1
Resources:
Abstract
5914 - Cancer, Mental Health and End Life Simulation (CAMhELS): A novel effectiveness evaluation.
Presenter: Asanga Fernando
Session: Poster Display session 1
Resources:
Abstract
2597 - Cancer patients’ expectations and understanding about their disease
Presenter: Mónica Pinho
Session: Poster Display session 1
Resources:
Abstract
5187 - Impact of patients’ death on oncologists and coping strategies: An online survey
Presenter: Soumaya Labidi
Session: Poster Display session 1
Resources:
Abstract
4579 - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Presenter: Andrea Sbrana
Session: Poster Display session 1
Resources:
Abstract
5058 - Preparedness for caregiving in caregivers of cancer patients
Presenter: Hatice Yakar
Session: Poster Display session 1
Resources:
Abstract
5917 - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement
Presenter: Carintia Dorta Pérez
Session: Poster Display session 1
Resources:
Abstract
4077 - The Reality of Critical Cancer Patients in a Polyvalent Intensive Care Unit
Presenter: Tiago Filipe Da Cruz Tomas
Session: Poster Display session 1
Resources:
Abstract
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract